Market expansion NOWDiagnostics focuses on OTC and POC diagnostics with a global market reach through First To Know and ADEXUSDx lines. PotentialSales: target professional settings and direct-to-consumer channels in regions with rising demand for rapid onsite testing, leveraging current partnerships and Labcorp distribution to broaden geographic coverage.

Strategic partnerships Key investors include Labcorp Venture Fund and a Labcorp distribution collaboration. PotentialSales: pursue co-marketing and co-development opportunities with Labcorp and other large healthcare distributors to scale the First To Know Syphilis Test and other immunoassay platforms across clinics, urgent care, and retail channels.

Product leadership Strong patent portfolio with First To Know and ADEXUSDx product lines enabling onsite one-step immunoassays. PotentialSales: position NOWDx as a turnkey solution for rapid diagnostics in workplaces, schools, and community health programs, emphasizing speed, accuracy, and minimal sample requirements to drive adoption.

Growth momentum Recent leadership change with a new CEO in 2026 and ongoing funding rounds including a Series B. PotentialSales: engage with leadership during next growth phase to align on enterprise and healthcare-system deployments, explore multi-year contracts for test kits and related consumables.

Portfolio fit Experience across COVID-19 serology development and syphilis testing, with manufacturing headquartered in Springdale, Arkansas. PotentialSales: offer complementary surveillance and confirmatory testing bundles for community clinics, mobile testing programs, and public health initiatives seeking rapid, affordable diagnostics at the point of care.